These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32511285)

  • 1. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.
    Morse JS; Lalonde T; Xu S; Liu WR
    ChemRxiv; 2020 Jan; ():. PubMed ID: 32511285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.
    Morse JS; Lalonde T; Xu S; Liu WR
    Chembiochem; 2020 Mar; 21(5):730-738. PubMed ID: 32022370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19.
    Rabie AM
    Curr Res Pharmacol Drug Discov; 2021; 2():100055. PubMed ID: 34870153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances Towards Drug Design Targeting the Protease of 2019 Novel Coronavirus (2019-nCoV).
    Bano S; Hameed A; Al-Rashida M; Iftikhar S; Iqbal J
    Curr Med Chem; 2021; 28(22):4484-4498. PubMed ID: 33109027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lawal B; Tsai SK; Wu ATH; Huang HS
    Arab J Chem; 2023 May; 16(5):104654. PubMed ID: 36777994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
    Kruse RL
    F1000Res; 2020; 9():72. PubMed ID: 32117569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment.
    Muhammed Y
    Biosaf Health; 2020 Dec; 2(4):210-216. PubMed ID: 32838282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research.
    Souza Rocha W; Zhan P; Ferreira da Silva-Júnior E
    Curr Top Med Chem; 2023; 23(17):1625-1639. PubMed ID: 37055893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).
    Dong S; Sun J; Mao Z; Wang L; Lu YL; Li J
    J Med Virol; 2020 Sep; 92(9):1542-1548. PubMed ID: 32181901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Malekmohammad K; Rafieian-Kopaei M
    Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
    Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
    J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.
    Zhang H; Saravanan KM; Yang Y; Hossain MT; Li J; Ren X; Pan Y; Wei Y
    Interdiscip Sci; 2020 Sep; 12(3):368-376. PubMed ID: 32488835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An
    Alexpandi R; De Mesquita JF; Pandian SK; Ravi AV
    Front Microbiol; 2020; 11():1796. PubMed ID: 32793181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
    Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
    F1000Res; 2020; 9():576. PubMed ID: 32802318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.